Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D...

Area of Science:

• Pharmacology
• Immunology
• Cell Biology

Background:

• Lung inflammation involves increased pro-inflammatory cytokines and chemokines.
• FCBD:std (cannabidiol, cannabigerol, tetrahydrocannabivarin) reduces alveolar epithelial cell inflammation but not macrophage inflammation.
• Investigating combined anti-inflammatory effects of FCBD:std with corticosteroids and NSAIDs is crucial.

Purpose of the Study:

• To evaluate the synergistic anti-inflammatory effects of FCBD:std combined with corticosteroids and NSAIDs.
• To determine the impact of these combinations on cytokine and chemokine levels and gene expression in lung cells.
• To assess the effects on cyclo-oxygenase (COX) activity and gene expression.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) for protein level determination.
• Quantitative real-time PCR for gene expression analysis.
• In vitro assessment of cyclo-oxygenase (COX) activity inhibition.

Main Results:

• FCBD:std and diclofenac demonstrated synergistic reduction of IL-8 in macrophages and lung epithelial cells.
• The combination also reduced IL-6, IL-8, and CCL2 expression in co-cultures (2D and 3D models).
• FCBD:std and NSAIDs reduced COX-1 and COX-2 gene expression but not enzymatic activity.

Conclusions:

• FCBD:std and diclofenac exhibit synergistic anti-inflammatory effects in lung macrophages and epithelial cells.
• The combination's efficacy in reducing key inflammatory markers is demonstrated.
• Further pre-clinical and clinical studies are necessary to validate these findings for therapeutic applications.